Antares Pharma, Inc. / Fundamentals
Income statement
- Net revenue
€157.41M - Cost of goods sold
€60.58M - Gross profit
€96.83M - SG&A expenses
€65.94M - R&D expenses
€14.47M - EBITDA
€52.12M - D&A
€3.38M - EBIT
€48.81M - Interest expenses
€1.77M - EBT
€46.98M - Tax expenses
€10.54M - Net income
€36.43M
Cash flow statement
- Net deferred tax
€11.96M - Non-cash items
-€45.17M - Changes in working capital
€11.77M - Operating cash flow
€25.53M - Capex
€4.73M - Other investing cash flow
€3.44M - Net investing cash flow
-€1.72M - Total cash dividends paid
€0.00 - Issuance of common stock
€0.00 - Debt repayment
€0.00 - Other financing cash flow
-€18.61M - Net financing cash flow
-€18.61M - Foreign exchange effects
€0.00 - Net change in cash
€5.20M - Cash at end of period
€52.95M - Free cash flow
€30.27M
Balance sheet
- Cash and cash equivalents
€52.95M - Cash and short-term investments
€53.38M - Total receivables
€80.03M - Inventory
€9.95M - Other current assets
€3.86M - Total current assets
€147.22M - Property, plant & equipment
€25.93M - Goodwill
€939.51K - Intangible assets
€15.18M - Long-term investments
€0.00 - Other non-current assets
€1.03M - Total non-current assets
€72.13M - Total assets
€219.35M - Accounts payable
€17.06M - Short-term debt
€2.18M - Other current liabilities
€25.93M - Total current liabilities
€47.82M - Long-term debt
€19.69M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€20.73M - Total liabilities
€68.55M - Common stock
€1.46M - Retained earnings
-€153.29M - Other equity
-€588.59K - Total equity
€150.81M - Total liabilities and shareholders' equity
€219.35M
Company information
- Market capitalization
€0.00 - Employees
201 - Enterprise Value
-€41.96M
Company ratios
- Gross margin
-
61.5% Much better than peer group: -201.5% - EBITDA margin
-
33.1% Much better than peer group: -9,765.3% - EBIT margin
-
31.0% Much better than peer group: -11,843.9% - EBT margin
-
29.8% Much better than peer group: -7,683.6% - Net margin
-
23.1% Much better than peer group: -11,743.1% - ROE
-
24.2% Much better than peer group: -23.8% - ROA
-
16.6% Much better than peer group: -5,038.5% - Asset turnover
-
71.8% Much worse than peer group: 404.0% - FCF margin
-
13.2% Much better than peer group: -4,944.2% - FCF yield
0.0% - Efficiency ratio
66.9% - Net sales per employee
-
€783.11K - Net income per employee
-
€181.25K